Repros Therapeutics Inc.
) first quarter 2014 loss of 37 cents per share was narrower than
the year-ago loss of 41 cents per share and in line with the Zacks
Consensus Estimate. The narrower loss was due to higher number of
The company's revenues for the first quarter of 2014 were $2,000 as
compared to $1,000 in the year-ago period, reflecting higher
interest income as a result of higher cash balances.
Quarter in Details
Both general and administrative (G&A) expenses and research and
development (R&D) expenses were up during the reported quarter.
While G&A expenses increased 14.9% to $1.2 million, R&D
expenses were up 16.1% year over year to $7.3 million.
Androxal, the most advanced pipeline candidate at Repros, is being
evaluated for the treatment of secondary hypogonadism. Repros is
conducting two identical, 17-week, double-blind studies. These
studies (ZA-305 and ZA-304) will compare the safety and efficacy of
Androxal with a testosterone replacement therapy (topical gel) and
placebo. Both ZA-305 and ZA-304 will enroll 120 patients.
Top-line data from these studies are expected by Oct 2014. Repros
plans to submit a new drug application (NDA) to the U.S. Food and
Drug Administration (FDA) in the fourth quarter of 2014. We expect
investor focus to remain on Androxal updates.
Proellex is another candidate in Repros' pipeline. Proellex is
being developed for uterine fibroids and severe endometriosis (a
phase II study is ongoing). The company is planning to submit the
protocol for a phase II study on Proellex for the treatment of
Repros currently carries a Zacks Rank #4 (Sell). Some better-ranked
Gilead Sciences Inc.
Alexion Pharmaceuticals, Inc.
). While Gilead carries a Zacks Rank #1 (Strong Buy), Alexion
and Affymetrix hold a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
AFFYMETRIX INC (AFFX): Free Stock Analysis
ALEXION PHARMA (ALXN): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
REPROS THERAPEU (RPRX): Free Stock Analysis
To read this article on Zacks.com click here.